发明名称 |
Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity |
摘要 |
This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor. |
申请公布号 |
US9168250(B2) |
申请公布日期 |
2015.10.27 |
申请号 |
US201313855806 |
申请日期 |
2013.04.03 |
申请人 |
Centre National de la Recherche Scientifique-CNRS |
发明人 |
Compan Valerie |
分类号 |
A61K31/454;A61K31/445;C07K14/705;A61K38/00 |
主分类号 |
A61K31/454 |
代理机构 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
代理人 |
Oblon, McClelland, Maier & Neustadt, L.L.P. |
主权项 |
1. A method of treating a pathology associated with an obsessional behavior of a mammal in need thereof, wherein the pathology is anorexia, the method comprising administering a therapeutically effective amount of an antagonist of a 5-HT4 receptor, an inverse agonist of a 5-HT4 receptor, a pharmaceutically acceptable salt of the antagonist, or a pharmaceutically acceptable salt of the inverse agonist to the mammal to treat the mammal. |
地址 |
Paris FR |